Genertec Universal Medical Group Company Limited
Genertec Universal Medical Group Company Limited Fundamental Analysis
Genertec Universal Medical Group Company Limited (2666.HK) shows moderate financial fundamentals with a PE ratio of 4.72, profit margin of 14.85%, and ROE of 11.53%. The company generates $14.8B in annual revenue with weak year-over-year growth of 0.10%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 35.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 2666.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2666.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent2666.HK trades at attractive valuation levels.
Growth Score
Moderate2666.HK shows steady but slowing expansion.
Financial Health Score
Moderate2666.HK shows balanced financial health with some risks.
Profitability Score
Weak2666.HK struggles to sustain strong margins.
Key Financial Metrics
Is 2666.HK Expensive or Cheap?
P/E Ratio
2666.HK trades at 4.72 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 2666.HK's PEG of -3.01 indicates potential undervaluation.
Price to Book
The market values Genertec Universal Medical Group Company Limited at 0.54 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -15.33 times EBITDA. This is generally considered low.
How Well Does 2666.HK Make Money?
Net Profit Margin
For every $100 in sales, Genertec Universal Medical Group Company Limited keeps $14.85 as profit after all expenses.
Operating Margin
Core operations generate 57.47 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.53 in profit for every $100 of shareholder equity.
ROA
Genertec Universal Medical Group Company Limited generates $2.60 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Genertec Universal Medical Group Company Limited generates strong operating cash flow of $5.05B, reflecting robust business health.
Free Cash Flow
Genertec Universal Medical Group Company Limited generates strong free cash flow of $4.07B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $2.02 in free cash annually.
FCF Yield
2666.HK converts 39.31% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
4.72
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-3.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.54
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.70
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
2.60
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.64
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.13
vs 25 benchmark
How 2666.HK Stacks Against Its Sector Peers
| Metric | 2666.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 4.72 | 18.56 | Better (Cheaper) |
| ROE | 11.53% | 828.00% | Weak |
| Net Margin | 14.85% | -175.00% (disorted) | Strong |
| Debt/Equity | 2.60 | 1.00 | Weak (High Leverage) |
| Current Ratio | 3.64 | 663.54 | Strong Liquidity |
| ROA | 2.60% | -21308.00% (disorted) | Weak |
2666.HK outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Genertec Universal Medical Group Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
83.76%
Industry Style: Value, Dividend, Cyclical
High GrowthEPS CAGR
20.19%
Industry Style: Value, Dividend, Cyclical
High GrowthFCF CAGR
156.63%
Industry Style: Value, Dividend, Cyclical
High Growth